Annovis Bio, Inc. (ANVS)
NYSE: ANVS · IEX Real-Time Price · USD
9.28
+4.01 (76.09%)
At close: Jul 2, 2024, 4:00 PM
9.60
+0.32 (3.45%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.
The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Annovis Bio, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Maria L. Maccecchini Ph.D. |
Contact Details
Address: 101 Lindenwood Drive, Suite 225 Malvern, Pennsylvania 19355 United States | |
| Phone | 484-875-3192 |
| Website | annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Chief Executive Officer, President and Executive Director |
| Henry Hagopian III, M.B.A. | Chief Financial Officer |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research and Development |
| Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Melissa Gaines | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | 8-K | Current Report |
| Jun 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 11, 2024 | 8-K | Current Report |
| Jun 5, 2024 | 8-K | Current Report |
| May 21, 2024 | 8-K | Current Report |
| May 13, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |